Retatrutide

What it is: A next-generation triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously — the most aggressive incretin compound currently in development.

What it does: In phase 2 trials, users averaged ~24% body weight loss at 48 weeks — the strongest result ever recorded. You can expect powerful appetite suppression, faster fat loss than sema or tirz, and significant metabolic improvements.

How it's used: Once-weekly subcutaneous injection with very careful titration — starting low and ramping up over months.